Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin Lymphoma from the phase 2 CheckMate 205 study Meeting Abstract
| Authors: | Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G. P.; Fanale, M. A.; Armand, P.; Zinzani, P. L.; de Boer, J. P.; on behalf of LLPC (Lunenburg PhaseI/II Consortium); Shipp, M. A.; Santoro, A.; Timmerman, J. M.; Sacchi, M.; Sy, O.; Kuruvilla, J. |
| Abstract Title: | Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin Lymphoma from the phase 2 CheckMate 205 study |
| Meeting Title: | 58th Annual Scientific Meeting of the British Society for Haematology |
| Keywords: | disease progression; outcomes; classical hodgkin lymphoma; trial; progressive disease; phase 2; relapsed/refractory; nivolumab; pd-1 inhibitor; tumour burden |
| Journal Title: | British Journal of Haematology |
| Volume: | 181 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Apr 16-18 |
| Meeting Location: | Liverpool, UK |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2018-04-01 |
| Start Page: | 87 |
| End Page: | 88 |
| Language: | English |
| ACCESSION: | WOS:000430117900111 |
| PROVIDER: | wos |
| PUBMED: | 29658101 |
| DOI: | 10.1111/bjh.15226 |
| Notes: | Meeting Abstract: BSH18-PO-080 -- 58th Annual Scientific Meeting of the British-Society-for-Haematology -- APR 16-18, 2018 -- Liverpool, ENGLAND -- 1 -- SI -- Source: Wos |
